By Wayne Kuznar
Although biomarker progress is easily discernible in cardiology and oncology, researchers are only at the beginning of the long, winding road of biomarker discovery in lupus, said Mary K. Crow, MD, Physician-in-Chief, and Chair, Division of Rheumatology, and Director of the Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York City, at the 2012 meeting of the American College of Rheumatology.
By Phoebe Starr
The goal of treating lupus is to induce improvement and maintain it, said Bevra Hahn, MD, Chief, Department of Rheumatology and Arthritis, University of California at Los Angeles.
By David Hawk
Berlin, Germany—A small study presented during a press conference at the 2012 European League Against Rheumatism Congress sparked a great deal of interest among rheumatology researchers when it was reported that use of the cancer drug bortezomib showed a dramatic reduction in symptom scores in patients with systemic lupus erythematosus (SLE) who are refractory to the current standard of care.
For patients with lupus nephritis who have responded to induction therapy, mycophenolate mofetil (CellCept) is superior to azathioprine (Azasan) in maintaining a renal response to treatment and in preventing relapse, according to a recent study…
Posted in 
